Zivo Bioscience, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Zivo Bioscience, Inc. filed its 2023 10-K report detailing its financial performance and business operations.</b>

AI Summary

Zivo Bioscience, Inc. (ZIVOW) filed a Annual Report (10-K) with the SEC on March 15, 2024. Zivo Bioscience, Inc. reported its 2023 fiscal year-end results on March 15, 2024. The company's principal executive offices are located at 21 E. Long Lake Road, Suite 100, Bloomfield Hills, MI 48304. Zivo Bioscience, Inc. was formerly known as HEALTH ENHANCEMENT PRODUCTS INC and WESTERN GLORY HOLE INC. The company operates in the Biological Products (No Diagnostic Substances) industry, SIC code 2836. The filing covers the fiscal year ending December 31, 2023.

Why It Matters

For investors and stakeholders tracking Zivo Bioscience, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Zivo Bioscience's financial health, operational status, and strategic direction for the fiscal year 2023. Investors and stakeholders can use this report to assess the company's performance, identify potential risks, and make informed investment decisions.

Risk Assessment

Risk Level: medium — Zivo Bioscience, Inc. shows moderate risk based on this filing. The company's financial performance and operational details are not fully elaborated in the provided header data, suggesting a need for deeper analysis of the full filing to assess its financial health and future prospects.

Analyst Insight

Review the full 10-K filing to understand Zivo Bioscience's revenue streams, expenses, and any significant changes in its business operations or financial condition.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-03-15 — Filing Date (Filed as of date)
• 001-40449 — SEC File Number (SEC file number)
• 24755498 — Film Number (Film number)

Key Players & Entities

• Zivo Bioscience, Inc. (company) — Filer name
• HEALTH ENHANCEMENT PRODUCTS INC (company) — Former company name
• WESTERN GLORY HOLE INC (company) — Former company name
• 21 E. Long Lake Road, Suite 100, Bloomfield Hills, MI 48304 (address) — Business and mailing address
• NV (jurisdiction) — State of incorporation
• 2836 (industry_code) — Standard Industrial Classification

FAQ

Industry Context

The company operates within the Biological Products sector, focusing on products that are not diagnostic substances.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring public companies to disclose material information about their business, financial condition, and operations.

What Investors Should Do

1. Analyze the full 10-K for detailed financial statements, including revenue, net income, and balance sheet information.
2. Investigate the 'Risk Factors' section for potential challenges and uncertainties facing Zivo Bioscience.
3. Review management's discussion and analysis (MD&A) for insights into the company's strategy and outlook.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-03-15: Filing Date — Date the 10-K report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial filing data provided for Zivo Bioscience, Inc.'s 2023 10-K. No prior filing data is available for comparison in this extract.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share ZIVO OTCQB Wa
• $9.2 billion — th market as a whole were approximately $9.2 billion in 2020, $753.0 million in 2020, and $3
• $753.0 million — ere approximately $9.2 billion in 2020, $753.0 million in 2020, and $3.9 billion in 2019, resp
• $3.9 billion — on in 2020, $753.0 million in 2020, and $3.9 billion in 2019, respectively. During the same
• $11.8 billion — panion animal market were approximately $11.8 billion in 2020 and $637.6 million in 2019, res
• $637.6 million — approximately $11.8 billion in 2020 and $637.6 million in 2019, respectively. Poultry Gut He
• $40.0 billion — antidiabetic markets were approximately $40.0 billion in 2020, $37.9 billion in 2019, $110.0
• $37.9 billion — re approximately $40.0 billion in 2020, $37.9 billion in 2019, $110.0 billion in 2017 and $48
• $110.0 billion — billion in 2020, $37.9 billion in 2019, $110.0 billion in 2017 and $48.8 billion in 2018, resp
• $48.8 billion — ion in 2019, $110.0 billion in 2017 and $48.8 billion in 2018, respectively. Beyond arthritis

Filing Documents

• zivo_10k.htm (10-K) — 1389KB
• zivo_ex211.htm (EX-21.1) — 7KB
• zivo_ex231.htm (EX-23.1) — 2KB
• zivo_ex311.htm (EX-31.1) — 7KB
• zivo_ex312.htm (EX-31.2) — 8KB
• zivo_ex321.htm (EX-32.1) — 3KB
• zivo_ex322.htm (EX-32.2) — 3KB
• 0001654954-24-003228.txt (&nbsp;) — 5974KB
• zivo-20231231.xsd (EX-101.SCH) — 61KB
• zivo-20231231_lab.xml (EX-101.LAB) — 318KB
• zivo-20231231_cal.xml (EX-101.CAL) — 45KB
• zivo-20231231_pre.xml (EX-101.PRE) — 270KB
• zivo-20231231_def.xml (EX-101.DEF) — 156KB
• zivo_10k_htm.xml (XML) — 1020KB

Business

Business 5 Item 1A.

Risk Factors

Risk Factors 26 Item 1B. Unresolved Staff Comments 37 Item 1C. Cybersecurity 37 Item 2.

Properties

Properties 37 Item 3.

Legal Proceedings

Legal Proceedings 37 Item 4. Mine Safety Disclosures 37 PART II. Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 38 Item 6. [Reserved] 38 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 38 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 43 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 44 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 44 Item 9A.

Controls and Procedures

Controls and Procedures 44 Item 9B. Other Information 46 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 46 PART III. Item 10. Directors, Executive Officers and Corporate Governance 47 Item 11.

Executive Compensation

Executive Compensation 47 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 47 Item 13. Certain Relationships and Related Transactions, and Director Independence 47 Item 14. Principal Accountant Fees and Services 47 PART IV. Item 15. Exhibits and Financial Statement Schedules 48 Item 16. Form 10-K Summary 49 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Some of the statements contained in this Annual Report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to statements regarding: our ability to continue as a going concern and our history of losses; our ability to obtain additional financing; our relatively new business model and lack of revenues; our ability to prosecute, maintain or enforce our intellectual property rights; disputes or other developments relating to proprietary rights and claims of infringement; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the implementation of our business model and strategic plans for our business and technology; the successful development of our production capabilities; the successful development of our sales and marketing capabilities; the potential markets for our products and our ability to serve those markets; the rate and degree of market acceptance of our products and any future products; our ability to retain key management personnel; regulatory developments and our com

Business

Item 1. Business. Unless we state otherwise or the context otherwise requires, references in this Annual Report on Form 10-K to "we," "our," "us," "ZIVO," "the Registrant" or "the Company" refer to Zivo Bioscience, Inc., a Nevada corporation, and its subsidiaries. Overview We are a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. We believe that our proprietary algal culture and materials derived therefrom show promise in benefiting both animal and human health, primarily through inflammation-modulating and immune-boosting properties. Overall, our efforts have been centered around two potential value-creating initiatives; the first being the identification of bioactive extracts or novel bioactive molecules from our proprietary algal culture to treat various diseases, and second, the utilization of our proprietary algal culture in its whole form as a food product to leverage its nutritional value. In the first quarter of 2022, we reformulated our biotech and agtech businesses around these two concepts. We reviewed the market potential (scale and profit) and the technical and business risks associated with each of the opportunities we had been working on and developed a focused strategy for each business. Available Information. We maintain an internet website at https://ir.zivobioscience.com. We make available on or through our website, free of charge, our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as soon as reasonably practical after we electronically file such material with, or furnish i

View Full Filing

View this 10-K filing on SEC EDGAR